

Validation data for Anti-hCD27-hIgG1

<https://www.invivogen.com/anti-hcd27-mabs>

For research use only

Version 23J04-AK

Anti-hCD27-hIgG1 is a recombinant monoclonal antibody (mAb) featuring the human (h) CD27-targeting variable region and the hIgG1 constant region of the clinical relevant mAb varlilumab. CD27 is a member of the TNFR family and the sole receptor for CD70 (aka CD27L). It is expressed by mature T cells as well as various cancer cells. The detection of hCD27 by Anti-hCD27-hIgG1 has been verified by flow cytometry using Raji-Null cells, which endogenously express CD27 (Figure 1). The induction of ADCC has been validated using InvivoGen's Raji-Null and Jurkat-Lucia™ NFAT-CD16 reporter cells (Figure 2).

Binding of Anti-hCD27-hIgG1 mAb to hCD27




Figure 1. Binding of Anti-hCD27-hIgG1 mAb to hCD27. Raji-Null cells were incubated for 30 minutes with 2 µg of Anti-hCD27-hIgG1 or an isotype control. Subsequently, a secondary PE-labeled antibody was added and incubated at room temperature for 30 minutes. The binding affinity was assessed using flow cytometry.

Comparison of ADCC induction of Anti-hCD27mAbs




Figure 2. Comparison of ADCC potency for native and engineered anti-human CD27 antibody isotypes. Raji-Null cells were incubated with gradient concentrations of Anti-hCD27 or Anti-β-galactosidase (β-gal) mAbs for 1 hour. Jurkat-Lucia™ NFAT-CD16 effector cells were then co-incubated with target Raji-Null cells for 6 hours. NFAT activation, reflecting the induced ADCC response, was assessed by determining Lucia luciferase activity in the supernatant using QUANTI-Luc™ 4 Lucia/Gaussia. Percentages of the maximal response normalized to the IgG1 isotype are shown.

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873
InvivoGen USA (International): +1 (858) 457-5873
InvivoGen Europe: +33 (0) 5-62-71-69-39
InvivoGen Asia: +852 3-622-34-80
E-mail: info@invivogen.com

 **InvivoGen**
www.invivogen.com